NIH funding: agency rebuts critique
We disagree with Joshua Nicholson and John Ioannidis' claim that the peer-review system of the US National Institutes of Health (NIH) works against genuinely innovative research, because we believe that their analysis is flawed (Nature 492, 34-36; 2012) .
They use 1,000 or more citations as a proxy for identifying breakthrough discoveries. However, more than 60% of the 158 highly cited articles they analyse cannot be categorized as innovative primary research: 34% are reviews, reports, clinical guidelines or descriptions of resources; 18% are clinical trials of the type primarily funded by industry; and 11% fall outside the NIH mandate that research should have the potential to improve human health (for our analysis, see http://dpcpsi.nih. gov/opa/natcorr).
Excluding these articles leaves 58 of the original 158: of these, 83% were funded by the NIH and 17% were funded by private industry.
The The authors' analyses depend on grant acknowledgments (75-83% in both series) but these are a problematic metric because they represent grants that were awarded 10-15 years ago when the NIH budget was expanding and acceptance rates were highest. Also, any of several co-authors can acknowledge a funding source if they are under pressure to demonstrate grant-related productivity, even if that source is irrelevant. And let's imagine a hypothetical funding system that forces all geniuses to quit science: 100% of papers could still acknowledge funding.
Groundbreaking projects account for less than 1% of awarded grants. Students whose papers reach 1,000 or more citations should certainly become principal investigators: stars will abandon systems that stifle independence. 
